WARF-University of Wisconsin/Thiogen Pharma, WI, United States
A new orally-administered, systemic aminothiol radioprotector, with no nausea/hypotension side effects, with issued and pending patents; itâ€™s administered minutes before a CT scan to prevent the 30,000 CT-associated cancers/year that are estimated by NCI to occur in the U.S. alone. We estimate a $2.9 Billion annual market in the U.S.
Primary Application Area: Biotech & Biological Sciences
Technology Development Status: Proven Manufacturability
Technology Readiness Level: TRL 7
FIGURES OF MERIT
Value Proposition: By peer-reviewed NCI estimate, CT scan radiation is associated with 30,000 cancers/year in U.S. (2% of annual total). Based upon human data in hand, this technology could prevent these 30,000 annual cancers in U.S., and up to 3% of cancers in western society. There is no existing radioprotector alternative.
Organization Type: Mid-stage Startup (A or B)
Showcase Booth #: 49M
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: Phase I ($0.1M) and Phase II ($1.34M) SBIR grants from NCI were awarded to support initial efforts to develop PrC-210 molecule as a topical radioprotector to prevent radiation dermatitis. PrC-210 is 100% effective in this role, but it was displaced internally by an alternate strategy. PrC-210 as a systemically administered radioprotector was then explored and developed. State of Wisconsin, WARF-UW and equity investment, for a total of $2.67 million to date, has been invested in PrC-210 preclinical, GLP PK studies (Covance), and rodent toxicology studies to date. Four peer-reviewed journal articles to date.
Primary Sources of Funding: Venture Capital, Federal Grant, University
Looking for: Both Funding and Development Partners